Forteo：飽和市場における画期的治療法の導入ケーススタディ

Abstract

Introduction

• The osteoporosis market has grown near% per year sin00, presenting many
• opportunities for drug manufacturers. However, several effective, well-established, and
• reasonably priced agents dominate the market. Even novel therapies satisfying a distinct need
• face tremendous challenges when launched in this competitive arena.

Get the Answers You Need to Shape Your Strategy

Eli Lilly' s bone-building drug Forteo (teriparatide) was a promising breakthrough treatment for osteoporosis that achieved disappointing sales and relatively low acceptance among patients and physicians. Why did Forteo fail to meet early expectations for its use? Several issues during Forteo' s development phase greatly affected its launch and initial uptake. What are some problems that can hinder the uptake of a breakthrough therapy? What lessons can be learned from Forteo' s development and launch? Even an effective novel agent may face challenges when placed in a market that is saturated with well-established therapies. What factors must drug developers consider when developing and launching new agents?

Scope

• Overview of osteoporosis: disease description, prevalence, and economic burden.
• Current market for osteoporosis therapies: overview of common agents used to treat osteoporosis.
• Case study of Forteo: development and approval, launch and early performance, outlook, lessons to be learned.

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• An Overview of Osteoporosis
• Disease Description, Prevalence, and Economic Burden
• Current Treatments
• Bisphosphonates
• SERMs
• Osteoporosis Mark5
• Case Study: Forteo
• Forteo' s Development and Approval
• Forteo' s Launch and Early Performance
• The Outlook for Forteo
• What Can Be Learned from Forteo?

Tables

• 1. Leading Therapies for the Treatment of Osteoporosis
• 2. Factors Limiting the Use of Forteo

Figures

• 1. Diagram of Bone Remodeling
• 2. Targets for Current Drugs in the Bone Remodeling Process
• 3. Market Share of Leading Drug Classe05
• 4. Quarterly Sales of Forte6